Efficient GPCR Drug Discovery by combining Novel Cell-Based Kinetic Assays with Systems Biology

InterAx Biotech

InterAx is a Swiss Biotech company spinoff from the ETH Zürich and Paul Scherrer Institute.

InterAx is developing different assets for the discovery of functionally optimized drugs with improved efficacy and reduced side effects for the largest class of human receptors: the G-Protein coupled Receptors (GPCRs).

The uniqueness of InterAx lies in the combination of protein-based IP-protected biosensors, kinetic signaling assays and mathematical modeling of signaling pathways. Besides opening new doors in classical drug discovery, the InterAx technology presents high relevance in precision medicine.